Drug Combination Details
| General Information of the Combination (ID: C44840) | |||||
|---|---|---|---|---|---|
| Name | Betulinic Acid NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | DDIT3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H358 | CVCL_1559 | Lung adenocarcinoma | Homo sapiens | |||
| A-427 | CVCL_1055 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Capan-1 | CVCL_0237 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Sorafenib in combination with betulinic acid synergistically induces cell cycle arrest and inhibits clonogenic activity in pancreatic ductal adenocarcinoma cells. | |||||
